https://medicalware.org/w/index.php?action=history&feed=atom&title=4D%E7%97%87%E5%80%99%E7%BE%A4 2026-04-09T22:17:43Z このウィキのこのページに関する変更履歴 MediaWiki 1.39.0 https://medicalware.org/w/index.php?title=4D%E7%97%87%E5%80%99%E7%BE%A4&diff=6138&oldid=prev 2020-09-24T02:23:05Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ja"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← 古い版</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2020年9月24日 (木) 11:23時点における版</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l10">10行目:</td> <td colspan="2" class="diff-lineno">10行目:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* [[うつ病]] (depression)</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* [[うつ病]] (depression)</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*: 重度の慢性皮膚病に関連している可能性があります。</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*: 重度の慢性皮膚病に関連している可能性があります。</div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== 参考文献 ==</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: final analysis of the GioTag study</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: MJ Hochmair, et al, Future Oncology, 2020</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: https://www.futuremedicine.com/doi/10.2217/fon-2020-0740</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Owlstone Medical, 4D Pharma Sign Breath Biomarker Services Deal</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: staff reporter, 360Dx, 2017</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: https://360dx.com/biomarker-discovery-validation/owlstone-medical-4d-pharma-sign-breath-biomarker-services-deal</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* NICE Recommends Lynch Syndrome Testing for Colorectal Cancer Patients</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: 360Dx, 2017</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: https://www.360dx.com/policy-legislation/nice-recommends-lynch-syndrome-testing-colorectal-cancer-patients</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* MSI Tumor Analysis Implicates Lynch Syndrome in Several New Cancer Types</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: Precision Oncology News, 2018</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: https://www.precisiononcologynews.com/sequencing/msi-tumor-analysis-implicates-lynch-syndrome-several-new-cancer-types</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Sandia Researchers Combine Molecular, Immunoassays for Syndromic Testing</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: Madeleine Johnson, 360Dx, 2018</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: https://www.360dx.com/pcr/sandia-researchers-combine-molecular-immunoassays-syndromic-testing</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Lynch Syndrome Mutation Study Suggests Changes to Clinical Management</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: Precision Oncology News, 2019</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*: https://www.precisiononcologynews.com/cancer/lynch-syndrome-mutation-study-suggests-changes-clinical-management</ins></div></td></tr> </table>

1.79.84.178 https://medicalware.org/w/index.php?title=4D%E7%97%87%E5%80%99%E7%BE%A4&diff=6137&oldid=prev 2020-09-24T02:20:38Z

<p>ページの作成:「&#039;&#039;&#039;4D症候群&#039;&#039;&#039;とは、<a href="/w/index.php?title=%E8%86%B5%E8%87%93%E5%86%85%E5%88%86%E6%B3%8C%E8%85%AB%E7%98%8D&amp;action=edit&amp;redlink=1" class="new" title="膵臓内分泌腫瘍 (存在しないページ)">膵臓内分泌腫瘍</a>の一種である<a href="/w/index.php?title=%E3%82%B0%E3%83%AB%E3%82%AB%E3%82%B4%E3%83%8E%E3%83%BC%E3%83%9E&amp;action=edit&amp;redlink=1" class="new" title="グルカゴノーマ (存在しないページ)">グルカゴノーマ</a>の典型的な４つの<a href="/wiki/%E7%97%87%E7%8A%B6" title="症状">症状</a>を表現するために使用される用…」</p> <p><b>新規ページ</b></p><div>&#039;&#039;&#039;4D症候群&#039;&#039;&#039;とは、[[膵臓内分泌腫瘍]]の一種である[[グルカゴノーマ]]の典型的な４つの[[症状]]を表現するために使用される用語です。<br /> <br /> ４つの症状名の頭文字がすべて「D」で有ることに由来する。<br /> * [[皮膚炎]] (dermatitis)<br /> ** [[壊死性遊走性紅斑]] - 口周囲および性器周囲に発生しやすい、広範囲の[[発疹]]。<br /> ** 口腔内発疹（口角炎、口唇炎<br /> ** [[腫瘍]]を切除すると消失する傾向がある<br /> * 軽度[[糖尿病]] (diabetes mellitus)<br /> * [[深部静脈血栓症]] (deep vein thrombosis)<br /> * [[うつ病]] (depression)<br /> *: 重度の慢性皮膚病に関連している可能性があります。</div>

1.79.84.178